2016
DOI: 10.1016/s0140-6736(16)30272-0
|View full text |Cite
|
Sign up to set email alerts
|

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial

Abstract: Pfizer and GlaxoSmithKline.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

37
756
8
68

Year Published

2016
2016
2022
2022

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 1,015 publications
(869 citation statements)
references
References 21 publications
37
756
8
68
Order By: Relevance
“…All subjects received repeated brief smoking cessation counselling. The published trial report provides full details of the study design and efficacy outcome measures, and continuous abstinence at the end of treatment (weeks 9–12) and to the end of the study (weeks 9–24) 1. The trial protocol is registered with http://clinicaltrials.gov (NCT01456936).…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…All subjects received repeated brief smoking cessation counselling. The published trial report provides full details of the study design and efficacy outcome measures, and continuous abstinence at the end of treatment (weeks 9–12) and to the end of the study (weeks 9–24) 1. The trial protocol is registered with http://clinicaltrials.gov (NCT01456936).…”
Section: Methodsmentioning
confidence: 99%
“…They were recruited from 16 countries. A list of participating study sites was published previously 1. Supporting information, Table S1 details subject enrolment and site presence by country/region by treatment.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…In 2016 the results of the EAGLES trial was published. This trial randomized 8144 smokers to receive varenicline, transdermal NRT patch, bupropion or placebo, and found that for every 100 smokers allocated to varenicline compared with NRT there were 1.07 (95% CI = –0.08 to 2.21) fewer moderate and severe neuropsychiatric adverse events 13. While it is possible for trials to suffer from bias, this provides the strongest evidence to date that varenicline does not cause neuropsychiatric adverse events 14.…”
mentioning
confidence: 99%